Abstract
We report a case of a 41-year-old man with acute myelogenous leukemia who developed fulminant hepatitis from reactivation of trace hepatitis B virus (HBV) 2 months after complete remission.Although he became positive for HB surface antigen at the onset of fulminant hepatitis, he had been negative for HBV serum markers, and only HBV DNA was detected by polymerase chain reaction (PCR) amplification on admission. The original stocks of serum samples from all blood donors were tested again for HBV DNA by PCR, and all samples were negative. This case demonstrates that testing for HBV DNA by PCR is necessary before chemotherapy, because silent HBV carriers are rare and fulminant hepatitis may be induced by chemotherapy in patients with hematologic malignancies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lok ASF, Liang RHS, Chiu EKW, Wong K-L, Chan T-K, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy.Gastroenterology. 1991;100:182–188.
Lau GKK, Liang R, Chiu EKW, Lee CK, Lam SK. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study.Bone Marrow Transplant. 1997;19:795–799.
Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: Survey in Japan, 1987–1991.Cancer. 1996;78:2210–2215.
Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.Nat Med. 1996;2:1104–1108.
Altfeld M, Rockstroh JK, Addo M, et al. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal.J Hepatol. 1998;29:306–309.
Grotz W, Rasenack J, Benzing T, et al. Occurrence and management of hepatitis B virus reactivation following kidney transplantation.Clin Nephrol. 1998;49:385–388.
Ohno R, Kobayashi T, Morishima Y, et al. Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).Leukemia. 1992;6:(Suppl 2)92–95.
Abe A, Inoue K, Tanaka T, et al. Quantitation of hepatitis B virus genomic DNA by real-time detection PCR.J Clin Microbiol. 1999;37:2899–2903.
Dusheiko G, Song E, Bowyer S, et al. Natural history of hepatitis B virus infection in renal transplant recipients—a fifteen-year follow-up.Hepatology. 1983;3:330–336.
Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.N Engl J Med. 1999;341:22–26.
Cacciola I, Pollicino T, Squadrito G, et al. Quantification of intra-hepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection.Hepatology. 2000;31:507–512.
Senecal D, Pichon E, Dubois F, Delain M, Linassier C, Colombat P. Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus.Bone Marrow Transplant. 1999;24:1243–1244.
Locasciulli A, Bacigalupo A, Van Lint MT, et al. Hepatitis B virus (HBV) infection and liver disease after allogeneic bone marrow transplantation: a report of 30 cases.Bone Marrow Transplant. 1990;6:25–29.
Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus.Lancet. 1996;347:92–93.
Author information
Authors and Affiliations
About this article
Cite this article
Ishiga, K., Kawatani, T., Suou, T. et al. Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia. Int J Hematol 73, 115–118 (2001). https://doi.org/10.1007/BF02981912
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02981912